Safety and efficacy of water-in-oil-in-water emulsion vaccines containing Newcastle disease virus haemagglutinin-neuraminidase glycoprotein

Fukanoki, Shinichi; Iwakura, Tadashi; Iwaki, S.; Matsumoto, Keīichi; Takeda, Reiji; Ikeda, Keiko; Shi, Zhe; Mori, Hajime

doi:10.1080/03079450120078707

Cited by 19 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(Snippe et al, 1981; Shakya and Nandakumar, 2013), and RHEODOL AO-15V (sorbitan sesquioleate) (Fukanoki et al, 2000, 2001). Three of these five compounds (i.e., ethanol, gum arabic, and RHEODOL AO-15V) were used to prepare the nanoemulsion W805EC, the OW-14 emulsion, and a water-in-oil-in-water emulsion, respectively (Fukanoki et al, 2000, 2001; Das et al, 2012; Galliher-Beckley et al, 2015) and showed their adjuvant effects as part of these emulsions; however, the adjuvant effect of each compound per se has not previously been shown. To our knowledge, this is the first report to demonstrate their adjuvanticity outside of an emulsion formulation.…”

Section: Resultsmentioning

confidence: 99%

Injectable Excipients as Novel Influenza Vaccine Adjuvants

et al. 2019

View full text Add to dashboard Cite

Influenza outbreaks can be either seasonal or pandemic. Vaccination is an effective strategy to control influenza; however, the efficacy of the currently available inactivated influenza virus vaccines is suboptimal, especially in the elderly. Vaccine efficacy can be improved by the addition of adjuvants, but few adjuvants have been approved for human vaccines. To explore novel, safe, and effective adjuvants for influenza vaccines, here we used a mouse model to screen 46 injectable drug additives approved in Japan. Of these 46 candidates, we identified 20 compounds that enhanced the efficacy of the split influenza HA vaccine against lethal virus challenge. These 20 compounds included 15 novel adjuvant candidates and 5 compounds with previously reported adjuvant effects for other antigens but not for influenza vaccine. Given that these additives are already approved for human use, the hurdle for their clinical use as novel and effective adjuvants for influenza or other vaccines is lower than for other adjuvant candidates whose safety profiles are unknown.

show abstract

Section: Resultsmentioning

confidence: 99%

Injectable Excipients as Novel Influenza Vaccine Adjuvants

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The vaccines are normally prepared in emulsions of mineral oil (water-in-oil) and administered intramuscularly or subcutaneously. It is generally required that the ratio of water phase to oil phase strikes a balance between the vaccine stability and its viscosity, such that the vaccine remains stable and yet not difficult to administer due to high viscosity of the emulsion [ 136 ]. Because these vaccines cannot replicate and spread horizontally among the vaccinated birds, they are not suitable for mass application.…”

Section: Vaccination Strategiesmentioning

confidence: 99%

Diagnostic and Vaccination Approaches for Newcastle Disease Virus in Poultry: The Current and Emerging Perspectives

Bello

Yusoff

Ideris

et al. 2018

BioMed Research International

View full text Add to dashboard Cite

Newcastle disease (ND) is one of the most devastating diseases that considerably cripple the global poultry industry. Because of its enormous socioeconomic importance and potential to rapidly spread to naïve birds in the vicinity, ND is included among the list of avian diseases that must be notified to the OIE immediately upon recognition. Currently, virus isolation followed by its serological or molecular identification is regarded as the gold standard method of ND diagnosis. However, this method is generally slow and requires specialised laboratory with biosafety containment facilities, making it of little relevance under epidemic situations where rapid diagnosis is seriously needed. Thus, molecular based diagnostics have evolved to overcome some of these difficulties, but the extensive genetic diversity of the virus ensures that isolates with mutations at the primer/probe binding sites escape detection using these assays. This diagnostic dilemma leads to the emergence of cutting-edge technologies such as next-generation sequencing (NGS) which have so far proven to be promising in terms of rapid, sensitive, and accurate recognition of virulent Newcastle disease virus (NDV) isolates even in mixed infections. As regards disease control strategies, conventional ND vaccines have stood the test of time by demonstrating track record of protective efficacy in the last 60 years. However, these vaccines are unable to block the replication and shedding of most of the currently circulating phylogenetically divergent virulent NDV isolates. Hence, rationally designed vaccines targeting the prevailing genotypes, the so-called genotype-matched vaccines, are highly needed to overcome these vaccination related challenges. Among the recently evolving technologies for the development of genotype-matched vaccines, reverse genetics-based live attenuated vaccines obviously appeared to be the most promising candidates. In this review, a comprehensive description of the current and emerging trends in the detection, identification, and control of ND in poultry are provided. The strengths and weaknesses of each of those techniques are also emphasised.

show abstract

“…In addition, an adjuvant formulation consisting of 35% v/v squalene emulsion emulsified with 15% v/v Arlacel ® A (mannide monooleate) mixed with a polycationic polyelectrolyte has been described [ 104 ]. Also of interest, a water-in-oil-in-water (w/o/w) squalene adjuvant was found to be safe and effective in protecting chickens against Newcastle disease virus [ 105 ]. It is composed of liquid paraffin (25%), squalene (10%), diglyceryl monooleate (5%), and Tween ® 80 (2%) in PBS.…”

Section: Vaccinesmentioning

confidence: 99%

Squalene Emulsions for Parenteral Vaccine and Drug Delivery

2009

View full text Add to dashboard Cite

Squalene is a linear triterpene that is extensively utilized as a principal component of parenteral emulsions for drug and vaccine delivery. In this review, the chemical structure and sources of squalene are presented. Moreover, the physicochemical and biological properties of squalene-containing emulsions are evaluated in the context of parenteral formulations. Historical and current parenteral emulsion products containing squalene or squalane are discussed. The safety of squalene-based products is also addressed. Finally, analytical techniques for characterization of squalene emulsions are examined.

show abstract

Safety and efficacy of water-in-oil-in-water emulsion vaccines containing Newcastle disease virus haemagglutinin-neuraminidase glycoprotein

Abstract: Subunit vaccines containing haemagglutinin-neuraminidase (HN) glycoprotein of

Cited by 19 publications

References 20 publications

Injectable Excipients as Novel Influenza Vaccine Adjuvants

Injectable Excipients as Novel Influenza Vaccine Adjuvants

Diagnostic and Vaccination Approaches for Newcastle Disease Virus in Poultry: The Current and Emerging Perspectives

Squalene Emulsions for Parenteral Vaccine and Drug Delivery

Contact Info

Product

Resources

About